{"id":"F2025L01607","name":"National Health (Weighted average disclosed price – April 2026 reduction day) Determination 2025","slug":"national-health-weighted-average-disclosed-price-april-2026-reduction-day-determination-2025","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"in_force","isInForce":true,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":107561,"registerId":"commonwealth-F2025L01607-current","compilationNumber":null,"startDate":"2026-04-03","status":"InForce","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"Name","content":"#### 1 Name\n\n(1) This instrument is the National Health (Weighted average disclosed price – April 2026 reduction day) Determination 2025.\n\n(2) This instrument may also be cited as PB 161 of 2025.","sortOrder":0},{"sectionNumber":"2","sectionType":"section","heading":"Commencement","content":"#### 2 Commencement\n\n(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.\n\n```html\n

Commencement information

Column 1

Column 2

Column 3

Provisions

Commencement

Date/Details

1. The whole of this instrument

The day after this instrument is registered.

20 December 2025

\n```\n\n(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.","sortOrder":1},{"sectionNumber":"3","sectionType":"section","heading":"Repeal","content":"#### 3 Repeal\n\nThe National Health (Weighted average disclosed price – October 2025 reduction day) Determination 2025 (PB 71 of 2025) is repealed.","sortOrder":2},{"sectionNumber":"4","sectionType":"section","heading":"Authority","content":"#### 4 Authority\n\nThis instrument is made under subsection 99ADB(4) and paragraph 99ADH(1)(aa) of the National Health Act 1953.","sortOrder":3},{"sectionNumber":"5","sectionType":"section","heading":"Definitions","content":"#### 5 Definitions\n\n> Note: A number of expressions used in this instrument are defined in section 99ADB of the Act, including the following:\n\n (a) adjusted approved ex-manufacturer price;\n (b) data collection period\n (c) unadjusted price reduction;\n (d) weighted average disclosed price.\n\nIn this instrument:\n\nAct means the National Health Act 1953.","sortOrder":4},{"sectionNumber":"Part 1","sectionType":"part","heading":"Brands of pharmaceutical items with a weighted average disclosed price; adjusted approved ex-manufacturer price and reduction day","content":"## Part 1 – Brands of pharmaceutical items with a weighted average disclosed price; adjusted approved ex-manufacturer price and reduction day","sortOrder":5},{"sectionNumber":"6","sectionType":"section","heading":"Weighted average disclosed price for brands of pharmaceutical items in Schedule 1","content":"#### 6 Weighted average disclosed price for brands of pharmaceutical items in Schedule 1\n\n(a) For subsection 99ADB(4) of the Act, the weighted average disclosed price of a brand of pharmaceutical item specified in column 2 of an item in the table to Schedule 1 is the amount specified in column 3 of that table item.\n\n(b) Subsection (a) applies in respect of a data collection period for a brand of pharmaceutical item ending on 30 September 2025.\n\nNote: Paragraph 99ADH(1)(a) of the Act applies if, under section 99ADB, the Minister determines the weighted average disclosed price of a brand of a pharmaceutical item in respect of a data collection period for the brand.","sortOrder":6},{"sectionNumber":"7","sectionType":"section","heading":"Adjusted approved ex-manufacturer price for brands of pharmaceutical items","content":"#### 7 Adjusted approved ex-manufacturer price for brands of pharmaceutical items\n\nThe adjusted approved ex-manufacturer price of a brand of pharmaceutical item specified in column 2 of the table to Schedule 1 is the amount equal to the amount of the weighted average disclosed price of that brand of pharmaceutical item determined under section 6 of this instrument.\n\nNote: Subsection 99ADB(7) of the Act provides that a determination made under subsection 99ADB(4) in relation to a brand of pharmaceutical item may include the adjusted approved ex-manufacturer price of the brand of pharmaceutical item.","sortOrder":7},{"sectionNumber":"8","sectionType":"section","heading":"Reduction Day","content":"#### 8 Reduction Day\n\nFor paragraph 99ADH(1)(aa) of the Act, a brand of pharmaceutical item specified in column 2 of an item in the table to Schedule 1 has a reduction day of 1 April 2026.","sortOrder":8},{"sectionNumber":"Part 2","sectionType":"part","heading":"Brands of pharmaceutical items with a weighted average disclosed price","content":"## Part 2 – Brands of pharmaceutical items with a weighted average disclosed price","sortOrder":9},{"sectionNumber":"9","sectionType":"section","heading":"Weighted average disclosed price for brands of pharmaceutical items in Schedule 2","content":"#### 9 Weighted average disclosed price for brands of pharmaceutical items in Schedule 2\n\n(a) For subsection 99ADB(4) of the Act, the weighted average disclosed price of a brand of pharmaceutical item specified in column 2 of an item in the table to Schedule 2 is the amount specified in column 3 of that table item.\n\n(b) Subsection (a) applies in respect of a data collection period for a brand of pharmaceutical item ending on 30 September 2025.\n\nNote: This instrument does not determine a reduction day for paragraph 99ADH(1)(aa) of the Act for a brand","sortOrder":10}],"analysis":{"kimi_summary":{"content_quality":"ok","complexity_score":4,"scope_assessment":{"changed":false,"description":"This instrument appears to serve its original narrow technical purpose under the National Health Act 1953. It is a routine administrative determination made under specific statutory powers to implement the price disclosure mechanism. There is no evidence of scope creep — it does exactly what its enabling provisions authorise: set WADP amounts, determine adjusted prices, and specify reduction days."},"complexity_factors":["Heavy reliance on external definitions — key terms like 'weighted average disclosed price', 'adjusted approved ex-manufacturer price', and 'data collection period' are defined in the National Health Act 1953, not this instrument","Cross-referencing to multiple provisions of the parent Act (subsections 99ADB(4), 99ADB(7), and paragraph 99ADH(1)(aa))","Two-tier structure with different legal consequences (Schedule 1 gets reduction day, Schedule 2 does not)","Repeal of a predecessor instrument (PB 71 of 2025) creating a temporal chain of instruments","Actual price data contained in unpublished schedules (Schedules 1 and 2 referenced but not included in the provided text)","Conditional application limited to data collection periods ending 30 September 2025"],"plain_english_summary":"This instrument updates PBS price-disclosure outcomes to set government-subsidised prices for specific prescription medicines from 1 April 2026. It fixes the weighted average disclosed price and adjusted ex‑manufacturer price used to calculate pharmacy reimbursements and manufacturer payments, repealing an earlier October 2025 determination.\n\nIt affects pharmaceutical companies, pharmacies, patients (via PBS co‑payments) and government budgets, and formalises market‑price‑driven subsidy reductions; Schedule 1 medicines also carry the 1 April 2026 reduction date."},"flash_summary":{"complexity_score":3,"scope_assessment":{"changed":true,"description":"This instrument replaces the earlier National Health (Weighted average disclosed price – October 2025 reduction day) Determination 2025 (repealed by section 3) and sets a new reduction day of 1 April 2026 for brands listed in Schedule 1 (section 8). It therefore changes the timing scope of the reduction previously tied to October 2025; Schedule 2 brands have prices set without a reduction day in this instrument (section 9)."},"complexity_factors":["Technical reliance on specific subsections of the National Health Act 1953 (99ADB and 99ADH) to give legal effect to price and reduction‑day determinations","Use of schedules to list multiple brands and numeric price entries rather than in‑text figures","Interaction with an identified data collection period (ending 30 September 2025) which ties the determination to past market data","Repeal of a prior instrument (PB 71 of 2025), altering previously announced timing for reductions","Differentiated treatment: Schedule 1 brands receive a reduction day while Schedule 2 brands have prices determined but no reduction day","Simple commencement rule (day after registration) but potential operational lead time for stakeholders"],"plain_english_summary":"This instrument fixes weighted average disclosed prices and—where stated—adjusted approved ex‑manufacturer prices for specified PBS brands for the data collection period ending 30 September 2025, and declares a reduction day of 1 April 2026 for the brands listed. It also repeals the earlier October 2025 reduction‑day determination. It affects listed medicine suppliers and the PBS pricing benchmarks that determine subsidy payments and manufacturer receipts, and begins the day after registration (20 December 2025)."},"flash_summary_failed":{"failed":true,"reason":"A positive credit balance is required for all requests, including BYOK, so fallback providers remain available. Add credits at https://vercel.com/d?to=%2F%5Bteam%5D%2F%7E%2Fai%3Fmodal%3Dtop-up to continue.","source":"analysis-cron"}},"importantCases":[],"_links":{"self":"/api/acts/national-health-weighted-average-disclosed-price-april-2026-reduction-day-determination-2025","history":"/api/acts/national-health-weighted-average-disclosed-price-april-2026-reduction-day-determination-2025/history","analysis":"/api/acts/national-health-weighted-average-disclosed-price-april-2026-reduction-day-determination-2025/analysis","conflicts":"/api/acts/national-health-weighted-average-disclosed-price-april-2026-reduction-day-determination-2025/conflicts","importantCases":"/api/acts/national-health-weighted-average-disclosed-price-april-2026-reduction-day-determination-2025/important-cases","documents":"/api/acts/national-health-weighted-average-disclosed-price-april-2026-reduction-day-determination-2025/documents"}}